The role of molecular physicochemical properties and apolipoproteins in association of drugs with triglyceride-rich lipoproteins: In-silico prediction of uptake by chylomicrons

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 1, 2009, Pages 31-39

  Gershkovich, Pavel ^a   Fanous, Joseph ^a   Qadri, Bashir ^a   Yacovan, Avihai ^b   Amselem, Shimon ^b   Hoffman, Amnon ^a,c  

^a School of Pharmacy   (Israel)

^b PHARMOS LTD   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Chylomicrons; In silico model; Lipophilic drugs; Lipoproteins; Physicochemical properties

Indexed keywords

ALPHA TOCOPHEROL; AMPHOTERICIN B; APOLIPOPROTEIN; APOMORPHINE; BENZO[A]PYRENE; BIFONAZOLE; CANNABINOID DERIVATIVE; CHYLOMICRON; CYCLOSPORIN A; DIAZEPAM; HALOFANTRINE; LIPOPROTEIN; PACLITAXEL; PROBUCOL; SIMVASTATIN; TESTOSTERONE; VITAMIN D;

ARTICLE; COMPUTER MODEL; DRUG STRUCTURE; DRUG UPTAKE; MALE; NONHUMAN; PHYSICAL CHEMISTRY; PREDICTION; RAT; VALIDATION STUDY;

EID: 58149218215     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.61.01.0005     Document Type: Article

References (32)

1. Wasan KM. Modifications in plasma lipoprotein concentration and lipid composition regulate the biological activity of hydrophobic drugs. J Pharmacol Toxicol Methods 1996; 36: 1-11.
2. Wasan KM, Cassidy SM. Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs. J Pharm Sci 1998; 87: 411-424.
3. Wasan KM. The role of lymphatic transport in enhancing oral protein and peptide drug delivery. Drug Dev Ind Pharm 2002; 28: 1047-1058.
4. Procyshyn RM et al. The effects of competitive displacement on haloperidol's plasma distribution in normolipidemic and hyperlipidemic plasma. Drug Dev Ind Pharm 2005: 31: 901-905
5. Brocks DR et al. The effect of increased lipoprotein levels on the pharmacokinetics of cyclosporine A in the laboratory rat. Biopharm Drug Dispos 2006; 27: 7-16.
6. Wasan KM et al. Role of plasma lipids and lipoproteins in predicting amphotericin B-induced nephrotoxicity in pediatric oncology patients. Cancer Chemother Pharmacol 2006: 57: 120-124.
7. Humberstone AJ et al. Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state. J Pharm Sci 1998; 87: 936-942.
8. Brocks DR, Wasan KM. The influence of lipids on stereoselective pharmacokinetics of halofantrine: important implications in food-effect studies involving drugs that bind to lipoproteins. J Pharm Sci 2002; 91: 1817-1826.
9. Mcintosh MP et al. Influence of physicochemical properties on the patterns of association of a series of aliphatic esters of halofantrine with plasma lipoproteins. J Control Release 2004; 95: 275-289.
10. Shayeganpour A et al. Pharmacokinetics of amiodarone in hyperlipidemic and simulated high fat-meal rat models. Biopharm Drug Dispos 2005; 26: 249-257.
11. Bassissi, MF et al. Influence of dyslipidemia on moxidectin distribution in plasma lipoproteins and on its pharmacokinetics. Pharm Res 2006; 23: 2672-2680.
12. Gershkovich P, Hoffman A. Effect of a high-fat meal on absorption and disposition of lipophilic compounds: the importance of degree of association with triglyceride-rich lipoproteins. Eur J Pharm Sci 2007; 32: 24-32.
13. Gershkovich P et al. The effect of a high-fat meal on the pharmacodynamics of a model lipophilic compound that binds extensively to triglyceride-rich lipoproteins. Int J Pharm 2007; 333: 1-4.
14. Hussain MM. A proposed model for the assembly of chylomicrons. Atherosclerosis 2000; 148: 1-15.
15. Hussain MM et al. Intestinal lipoprotein assembly. Curr Opin Lipidol 2005; 16: 281-285.
16. Mu H, Porsgaard T. The metabolism of structured triacylglycerols. Prog Lipid Res 2005; 44: 430-448.
17. Gershkovich P, Hoffman A. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability. Eur J Pharm Sci 2005; 26: 394-404.
18. Gershkovich P et al. Different impacts of intestinal lymphatic transport on the oral bioavailability of structurally similar synthetic lipophilic cannabinoids: dexanabinol and PRS-211,220. Eur J Pharm Sci 2007; 31: 298-305.
19. Porter CJ et al. Lymphatic transport of halofantrine in the triplecannulated anesthetized rat model: effect of lipid vehicle dispersion. J Pharm Sci 1996; 85: 351-356.
20. Tan L et al. [Determination of simvastatin in human plasma by high performance liquid chromatography]. Se Pu 2000; 18: 232-234.
21. Gabrielsson J et al. Multivariate methods in pharmaceutical applications. J Chemometrics 2002; 16: 141-160.
22. Eriksson L et al. Onion design and its application to a pharmaceutical QSAR problem. J Chemometrics 2004; 18: 188-202.
23. Wassvik CM et al. Contribution of solid-state properties to the aqueous solubility of drugs. Eur J Pharm Sci 2006; 29: 294-305.
24. Bergstrom CA et al. Poorly soluble marketed drugs display solvation limited solubility. J Med Chem 2007; 50: 5858-5862.
25. Kasim NA et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 2004; 1: 85-96.
26. Holm R, Hoest J. Successful in silico predicting of intestinal lymphatic transfer. Int J Pharm 2004; 272: 189-193.
27. Charman WN, Stella VJ. Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules. Int J Pharm 1986; 34: 175-178.
28. Myers RA, Stella VJ. Factors affecting the lymphatic transport of penclomedine (NSC-338720), a lipophilic cytotoxic drug: comparison to DDT and hexachlorobenzene. Int J Pharm 1992; 80: 51-62.
29. Hauss DJ et al. Targeted lymphatic transport and modified systemic distribution of CI-976, a lipophilic lipid-regulator drug, via a formulation approach. Int J Pharm 1994; 108: 85-93.
30. O'Driscoll CM. Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci 2002; 15: 405-415.
31. Fernando-Warnakulasuriya GJP et al. Lipoprotein metabolism in the suckling rat: characterization of plasma and lymphatic lipoproteins. J Lipid Res 1983; 24: 1626-1638.
32. Wasan KM et al. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nat Rev Drug Discov 2008; 7: 84-99.